Tharimmune (THAR) Stock Price, News & Analysis

Company Overview

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

Key Stats

• Today's Range: $4.13 to $6.09
• 50-Day Range: $1.17 to $3.59
• 52-Week Range: $0.95 to $6.39
• Volume: 102.85 million shs
• Average Volume: 3.02 million shs
• Market Capitalization: $26.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.00
• Consensus Rating: Strong Buy

Tharimmune Stock Analysis - MarketRank™

Tharimmune scored higher than 66% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Tharimmune has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Tharimmune has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Tharimmune is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tharimmune is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tharimmune has a P/B Ratio of 61.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.29% of the float of Tharimmune has been sold short.

Short Interest Ratio / Days to Cover

Tharimmune has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tharimmune has recently decreased by 50.00%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tharimmune does not currently pay a dividend.

Dividend Growth

Tharimmune does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.29% of the float of Tharimmune has been sold short.

Short Interest Ratio / Days to Cover

Tharimmune has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tharimmune has recently decreased by 50.00%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: -0.04

News Sentiment

Tharimmune has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Tharimmune this week, compared to 0 articles on an average week.

Search Interest

11 people have searched for THAR on MarketBeat in the last 30 days. This is an increase of 450% compared to the previous 30 days.

MarketBeat Follows

4 people have added Tharimmune to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Tharimmune insiders have bought more of their company's stock than they have sold. Specifically, they have bought $592,464.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

10.01% of the stock of Tharimmune is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 1.16% of the stock of Tharimmune is held by institutions.

THAR Stock Analysis - Frequently Asked Questions

How have THAR shares performed this year?

Tharimmune's stock was trading at $2.03 at the beginning of 2025. Since then, THAR stock has increased by 140.6% and is now trading at $4.8850.

How were Tharimmune's earnings last quarter?

Tharimmune, Inc. (NASDAQ:THAR) released its quarterly earnings results on Thursday, August, 14th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by $0.06.

When did Tharimmune's stock split?

Shares of Tharimmune reverse split on Tuesday, May 28th 2024.The 1-15 reverse split was announced on Tuesday, May 28th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Tharimmune's major shareholders?

Top institutional shareholders of Tharimmune include Franklin Resources Inc. (1.07%) and XTX Topco Ltd (0.31%). Insiders that own company stock include Gravitas Capital Lp, Sireesh Appajosyula, Randy Milby and Sanam Parikh.
View institutional ownership trends.

How do I buy shares of Tharimmune?

Shares of THAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Tharimmune own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tharimmune investors own include Jiuzi (JZXN), Avenue Therapeutics (ATXI), Scinai Immunotherapeutics (SCNI), Adial Pharmaceuticals (ADIL), Sphere 3D (ANY), Blackboxstocks (BLBX).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 8/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:THAR
• Previous Symbol: NASDAQ:THAR
• CIK: 1861657
• Web: www.hillstreambio.com
• Phone: 908-955-3140
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Tharimmune: $17.00
• High Price Target: $17.00
• Low Price Target: $17.00
• Potential Upside/Downside: +266.1%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.20 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,239.20%
• Return on Assets: -365.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.17
• Quick Ratio: 0.67

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.08 per share
• Price / Book: 58.04

Miscellaneous

• Outstanding Shares: 4,640,000
• Free Float: 4,171,000
• Market Cap: $21.54 million
• Optionable: Not Optionable
• Beta: 1.17